Microglial dynamics and neuroinflammation in prodromal and early Parkinson’s disease.

Publication date: May 21, 2025

Parkinson’s disease (PD) is characterized by a drastic loss of dopaminergic neurons already at diagnosis. As this loss of neurons starts decades before diagnosis, understanding the prodromal stages of the disease might offer novel strategies to curb its progression. While the precise pathogenic mechanisms underlying PD remain incompletely understood, growing evidence suggests that neuroinflammation and immune dysregulation play a central role in the development and progression of the disease. Here, we delve into the emerging roles of microglia, the resident immune cells of the central nervous system, in the pathogenesis of prodromal and early-stage PD. We emphasize that microglia contribute to neuroinflammation, protein aggregation and neurodegeneration, although the underlying mechanisms are not yet known. Neuroimaging studies have provided valuable insights into the patterns of microglial activation detected in individuals with prodromal PD and at the time of clinical diagnosis. Furthermore, we highlight the complex interplay between immune dysregulation and neurodegeneration along PD development, including alterations in the peripheral immune system, brain-gut interactions and brain-immune interfaces. Lastly, we outline existing models for investigating microglial involvement in prodromal PD, along with the impact of anti-inflammatory therapies and strategies to modify risk factors. In conclusion, targeting microglial activation and immune dysfunctions in individuals at risk of PD could represent a promising preventive measure and may offer novel therapeutic strategies for early intervention and disease modification.

Open Access PDF

Concepts Keywords
Decades Microglia
Neuroinflammation Neuroinflammation
Parkinson Parkinson’s disease
Pathogenesis Prodromal stage
Valuable REM-sleep behaviour disorder

Semantics

Type Source Name
disease MESH neuroinflammation
disease MESH Parkinson’s disease
disease MESH pathogenesis
pathway REACTOME Immune System
pathway REACTOME Reproduction
drug DRUGBANK Trestolone
disease MESH tremor
disease MESH tic
disease MESH Hyposmia
disease MESH oxidative stress
disease MESH infections
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Indoleacetic acid
disease MESH synucleinopathies
disease MESH Lewy body dementia
pathway REACTOME Metabolism
pathway REACTOME Autophagy
disease MESH mitochondrial dysfunction
disease MESH brain inflammation
drug DRUGBANK Coenzyme M
disease MESH inflammation
drug DRUGBANK Tretamine
pathway REACTOME Methylation
pathway REACTOME Release
drug DRUGBANK Dopamine
disease MESH dysbiosis
disease MESH inflammatory bowel diseases
disease MESH Crohn’s disease
disease MESH life style
drug DRUGBANK Ilex paraguariensis leaf
pathway REACTOME Fatty acids
disease MESH death
disease MESH influenza
disease MESH secondary Parkinsonism
disease MESH viral infections
disease MESH latent infections
disease MESH parkinsonism
disease MESH syndrome
disease MESH SARS COV 2 infection
disease MESH respiratory infections
disease MESH anxiety
disease MESH depression
disease MESH CNS infections
disease MESH polygenic risk scores
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH cognitive dysfunction
drug DRUGBANK Norepinephrine
disease MESH sleep deprivation
disease MESH insomnia
disease MESH sleep disorders
drug DRUGBANK Piroxicam
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK Nitric Oxide
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Iron
disease MESH bacterial infections
disease MESH Olfactory impairment
disease MESH astrogliosis
pathway KEGG Circadian rhythm
drug DRUGBANK Ambroxol
disease MESH physical inactivity
disease MESH sweating
disease MESH excessive daytime sleepiness
disease MESH Herpes simplex
disease MESH Multiple system atrophy
disease MESH herpes zoster
disease MESH rapid eye movement sleep behavior disorder
disease MESH Alzheimer’s disease
disease MESH neurologic signs
drug DRUGBANK Acetate ion
pathway KEGG Parkinson disease
disease MESH dementia
disease MESH histocompatibility
drug DRUGBANK Cyclic Adenosine Monophosphate
drug DRUGBANK Sulpiride
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Ibuprofen
drug DRUGBANK Pirenzepine
disease MESH mood disorders

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *